V3V.DE

VITA 34 AG [V3V.DE] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

V3V.DE Stock Summary

Top 10 Correlated ETFs

V3V.DE

Top 10 Correlated Stocks

V3V.DE

In the News

V3V.DE Financial details

Company Rating
-
Market Cap
83.32M
Income
-25.18M
Revenue
74.86M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
815
Optionable
No
Shortable
Yes
Earnings
29 May 2024
P/E
-3.35
Forward P/E
-
PEG
4.01
P/S
1.25
P/B
6.92
P/C
-
P/FCF
-66.05
Quick Ratio
0.05
Current Ratio
0.68
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-1.59
EPS next Y
-
EPS next Q
-
EPS this Y
-
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
30.56%
Revenue Q/Q
11.15%
EPS Q/Q
32.8%
-
-
-
-
SMA20
-16.67%
SMA50
-
SMA100
-16.67%
Inst Own
-
Inst Trans
-
ROA
-17%
ROE
-181%
ROC
-0.22%
Gross Margin
14%
Oper. Margin
-29%
Profit Margin
-34%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
3.69-7.32
52W High
-24.29%
52W Low
+76.67%
RSI
37
Rel Volume
3.93
Avg Volume
1.87K
Volume
7.36K
Perf Week
0%
Perf Month
-10.92%
Perf Quarter
-17.83%
Perf Half Y
3.92%
-
-
-
-
Beta
0.602
-
-
Volatility
0.03%, 0.29%
Prev Close
0.95%
Price
5.3
Change
-0.93%

Something similar

Top by Market Cap
V
AMZ.DE
VTSAX
MIX.JO
JPM
Top Correlated ETFs
291620.KS
251340.KS
250780.KS
275750.KS
301410.KS
Top Correlated Stocks
POAI
601766.SS
0QOB.L
AUTN.SW
2160.HK
Similar Market Cap
PHX
NBST
PR1G.DE
PBHC
FCRR.TO

Company Profile

Healthcare Medical - Care Facilities
  • Volume Average 1.87K
  • Market Capitalization 83.32M
  • Employee 815
  • CEO Mr. Jakub Julian Baran
  • Headquarters Leipzig,DE
  • IPO Date 2007-03-27
  • Website https://www.vita34.de

VITA 34 AG engages in the collection, processing, and storage of stem cells from umbilical cord blood and tissue in Germany, Spain, and internationally. It also develops cell therapeutic procedures; cell and gene therapies; cryopreservation of endogenous immune cells; and CAR-T. In addition, the company manufactures advanced therapy medicinal products based on mesenchymal stem cells for experimental treatment by specialized medical institutions; preserves stem cells from perinatal tissue and adult body fat; and engages in the contract manufacturing of pharmaceutical intermediates. VITA 34 AG was founded in 1997 and is based in Leipzig, Germany.